CardioMech
CardioMech is a Norwegian medical device company developing the CardioMech MVRS, a transcatheter mitral valve repair system using artificial chordal replacement to treat degenerative mitral regurgitation as a less-invasive alternative to open-heart surgery. It targets interventional cardiologists, cardiac surgeons, and DMR patients in Europe and the United States.
- Company typePrivate
- Founded2018
- HeadquartersTrondheim, Norway
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What CardioMech does
CardioMech AS is a privately held Norwegian medical device company developing the CardioMech MVRS (Mitral Valve Repair System), a transcatheter platform designed to treat degenerative mitral regurgitation (DMR) without open-heart surgery. The system deploys artificial chord(s) through a transfemoral, transseptal catheter to replace broken or elongated native chordae tendineae, restoring native valve anatomy on a beating heart under echocardiographic guidance. Procedures are designed to be simple and potentially sub-hour for straightforward cases, with the ability to deploy up to two chords for more complex anatomy, and the small implant size is intended to preserve future surgical or transcatheter therapy options. The device is positioned as a potential first-line transcatheter therapy for both surgery-eligible and surgery-ineligible DMR patients, targeting the same disease space as the $6B-plus TAVR market but for the mitral valve.
The company is headquartered in Trondheim, Norway, with US operations in Fridley, Minnesota to support clinical trials and regulatory engagement in the US market. CardioMech MVRS is investigational only and not approved for sale in any geography; an Early Feasibility Study is registered on clinicaltrials.gov. Leadership includes co-founders Jacob Bergsland (CMO) and Nikolai Hiorth (CTO), CEO/President Rick Nehm, and Chairman Ramin Mousavi, the former CEO of CathWorks (acquired by Medtronic for $585M in April 2026), who brings Edwards Lifesciences and Baxter experience.
The business model is a future medical-device hardware-sale model: revenue will ultimately be generated through sale of the artificial-chord implant and delivery system to hospitals and cardiac centers performing transcatheter mitral valve repair, supplemented by clinical training and support services. Pricing is not publicly disclosed because no commercial sales exist today. The company has raised approximately $84M cumulatively across eight disclosed rounds between 2019 and April 2025, with recent rounds led or backed by Hadean Ventures, Investinor, Aerion Partners, and an undisclosed strategic investor; all US capital raises have been registered via SEC Form D filings.
CardioMech firmographics
Firmographics- Name
- CardioMech
- Legal name
- CardioMech AS
- Website
- https://cardiomech.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CardioMech is a Norwegian medical device company developing the CardioMech MVRS, a transcatheter mitral valve repair system using artificial chordal replacement to treat degenerative mitral regurgitation as a less-invasive alternative to open-heart surgery. It targets interventional cardiologists, cardiac surgeons, and DMR patients in Europe and the United States.
- Ownership category
- akta.pro rank
CardioMech industry classification
Industry- Product category
- Structural Heart Medical Devices
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
Keywords
Where CardioMech is headquartered
LocationHeadquarters
- HQ city
- Trondheim
- HQ country
- Norway
- HQ region
- Europe
Offices2 records
Markets served
CardioMech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Medical Device Sales: As a medical device company developing an implantable device for transcatheter mitral valve repair, CardioMech will generate revenue through the sale of its artificial chord implants and associated delivery systems to hospitals and cardiac centers performing the procedures.
- Clinical Training and Support: Potential revenue from training, support, and clinical consultation services for hospitals and cardiac centers adopting the CardioMech MVRS platform.
Go-to-market motion2 records
CardioMech product offering
Product offeringCore offering
CardioMech is developing the CardioMech MVRS, a transcatheter mitral valve repair platform that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart. The system is intended as a less-invasive alternative to open-heart surgery for patients with degenerative mitral regurgitation, including those considered surgically ineligible. The device is for investigational use only and is not yet available for sale.
Product overview
CardioMech is developing the CardioMech MVRS (Mitral Valve Repair System), a transcatheter mitral valve repair platform. The system uses artificial chords designed to reduce or eliminate mitral regurgitation and restore native anatomy. It is a catheter-based therapy intended as an alternative to open-heart surgery and potentially as first-line therapy for degenerative mitral regurgitation patients, including both surgery-eligible and surgery-ineligible populations.
Differentiator
Problem solved
Functional benefit
Products and services
- CardioMech MVRS (Mitral Valve Repair System) A transcatheter mitral valve repair system that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart under echocardiographic guidance. Designed for simple, potentially sub-hour procedures in simple DMR cases with capability to deploy up to two chords in complex cases, intended as a less-invasive alternative to open-heart surgery and a candidate first-line therapy for degenerative mitral regurgitation. For investigational use only.
Quantifiable outcome
- Potential to reduce the need for open-heart surgery in degenerative mitral regurgitation patients
- +2 more outcomes
Companies that use CardioMech
Customer profileSegments2 records
Ideal customer profiles1 record
CardioMech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CardioMech partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
CardioMech competitors and assessment
Company assessmentEmerging players
- Anteris Technologies: Anteris Technologies is developing the DurAVR THV system for transcatheter aortic valve replacement and is expanding into structural heart. As a small-cap structural heart device developer with overlapping R&D and commercialization challenges, it is comparable in stage and category focus to CardioMech.
- Cardiac Dimensions: Cardiac Dimensions markets the Carillon System for transcatheter mitral annuloplasty to treat functional mitral regurgitation. It addresses the same mitral regurgitation patient population as CardioMech, albeit with a different anatomic mechanism (annuloplasty vs. chordal replacement).
- Polares Medical: Polares Medical is developing a transcatheter mitral valve replacement system targeting both functional and degenerative mitral regurgitation. As an emerging transcatheter mitral player, it competes for the same clinical and strategic attention as CardioMech within structural heart programs and investment flows.
- CroíValve: CroíValve is developing a transcatheter tricuspid and mitral coaptation device for patients with severe regurgitation. It is an emerging structural heart player addressing overlapping patient populations and competing for similar venture and strategic capital as CardioMech.
- 4C Medical Technologies: 4C Medical is developing the AltaValve system for transcatheter mitral valve replacement (TMVR). As an emerging structural heart company focused on mitral disease, it competes for the same patient population as CardioMech MVRS, though via replacement rather than repair.
Direct peers
- NeoChord: NeoChord develops the NeoChord DS1000 system for transapical, beating-heart artificial chord implantation to treat degenerative mitral regurgitation. It is the closest direct competitor to CardioMech MVRS, also using artificial chordal replacement, though with a transapical rather than transfemoral transseptal delivery approach.
Broad incumbents
- Edwards Lifesciences: Edwards Lifesciences is a dominant structural heart incumbent with the PASCAL transcatheter mitral repair system and the TAVR franchise (Sapien). Directly competes with CardioMech in transcatheter mitral valve repair and acquired Harpoon Medical (another chordal repair player), making it both a competitor and likely strategic acquirer.
- Medtronic: Medtronic acquired CathWorks (former employer of CardioMech Chairman Mousavi) for $585M and competes broadly in structural heart with Intrepid TMVR, the Harmony TPV, and its TAVR franchise. It is both a direct competitor in transcatheter mitral and a likely strategic acquirer of novel chordal repair platforms.
- Boston Scientific: Boston Scientific operates in structural heart and acquired Farapulse and Apollo Endosurgery as part of its growth strategy. While its mitral valve portfolio is more limited, it remains a broad incumbent with the resources and clinical infrastructure to compete with or acquire transcatheter mitral players like CardioMech.
- Abbott: Abbott markets the MitraClip, the most widely adopted transcatheter edge-to-edge mitral repair device, and the TriClip tricuspid system. It competes directly with CardioMech's transcatheter mitral approach and possesses the scale, sales force, and clinical evidence to defend share in structural heart.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CardioMech social profiles
Digital presenceCardioMech financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardioMech leadership team
Management profileNumber of profiles
Profiles4 records
CardioMech funding detail
Funding detailFunding overview
Funding rounds8 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardioMech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardioMech
What does CardioMech do?
CardioMech is developing the CardioMech MVRS, a transcatheter mitral valve repair platform that uses artificial chord(s) delivered via transfemoral, transseptal access to replace broken or elongated native chordae tendineae on a beating heart. The system is intended as a less-invasive alternative to open-heart surgery for patients with degenerative mitral regurgitation, including those considered surgically ineligible. The device is for investigational use only and is not yet available for sale.
Is CardioMech a public or private company?
CardioMech is a private company. It is classified as venture growth investor backed and is currently operating.
When was CardioMech founded?
CardioMech was founded in 2018. It employs 1 to 10 people.
Where is CardioMech based?
CardioMech is headquartered in Trondheim, Norway, in the Europe region.
How does CardioMech make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are clinical Training and Support.
Who are CardioMech's main competitors?
Emerging players on record are Anteris Technologies, Cardiac Dimensions, Polares Medical, CroíValve and 4C Medical Technologies. NeoChord is listed as a direct peer. Broad incumbents are Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.
Does CardioMech have an API?
No public API is recorded for CardioMech.
What industry is CardioMech in?
CardioMech's product category is Structural Heart Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair. Its NAICS code is 5417 and its SIC code is 3841.